Thanks for the encouraging news @grpetersen1 Clinical trials have helped all of our lives, thanks to patients like you. Good luck with finding your allo partner.
Profound sorry that my mentor, friend, and colleague, the legend Bob Kyle passed away. His contributions to patients, medicine, myeloma, @IMFmyeloma@MayoClinic myeloma group, and the institution are monumental. A role model who will be remembered for his integrity and commitment to patients. I owe my career to him. He leaves behind a legacy of experts at Mayo Clinic as well as world over who were influenced greatly by him.
See thread for links to a video an article on him that I wrote for @MayoProceedings
Post your memories below.
With the revision of IMS IMWG high risk myeloma definition to make it stricter, and relaxation of diagnostic criteria for plasma cell leukemia to 5% PCs, the two groups have come closer in outcomes. They share a need for new ways overcome risk and improve prognosis with unified clinical trials. We also need to eliminate confusion for patients
In our view Plasma Cell Leukemia is a form of high risk myeloma. The term captures risk the same way del17 or EMD captures risk.
My 2026 Update on Diagnosis, Risk Stratification, and Treatment of Myeloma is out! #OpenAccess
It’s current including all recent advances in immunotherapy. Managed to squeeze in iberdomide approval from 6 days ago! Bookmark!
onlinelibrary.wiley.com/doi/…
5. Lenalidomide for 2 years is as good as giving it indefinitely. (ENDURANCE trial) @NEJM 2026
This is an investigator initiated @theNCI funded clinical trial that I think is practice changing; reduces toxicity; and saves the country billions of $
Took 15 years start to finish. @myelomaMD spearheaded this @eaonc effort.
Similar to the Dexamethasone trial above, this type of trial can only be done an IIT through @theNCI funded mechanism, and you need a clear vision that while pharma trials find X treatment forever is better than nothing, we need IITs to determine how much of X is actually needed for the effect.
Good for you Gary @grpetersen1 Your persistence in seeking trials and self-education have been factors in your long MM survival. We wish the same for your MDS.
News on my 6 month battle with treatment related MDS (t-MDS) caused by my 20 year battle with high risk Multiple Myeloma. I got into a clinical trial.
myelomasurvival.com/myeloma-…
Because there is no effective treatment for t-MDS, I was on a mission to find one.
I hear from some academic faculty in medicine that they run trials, make important discoveries, but don’t get new opportunities and are not recognized compared to colleagues who are highly visible on social media who may have done less than them.
My advice: Unlike the past where your publications were sufficient you should consider social media to be important for academic success in addition to your lectures and publications. Especially if your goal is to change clinical practice and maximize the impact of your findings. Your voice on here is important. You also learn from here.
Of course, celebrity on social media is not what counts. What counts as always are your enduring contributions to research like finding new diagnostic tests, new mechanisms of action, new treatments. But your voice on platforms like X can affect how much your research contributes to patient care, by helping you disseminate the information, interpret your findings, and even make you sought after to lead new clinical trials etc.
Use social media to your advantage; treat it like writing mini-editorials or reviews. Use it to increase your knowledge of what’s happening in other related fields, make new connections, and helping colleagues. Writing on here means you have to be clear and concise. That actually helps you formulate your own ideas. Helps you get better at writing and communication.
Add your thoughts! If you are a leader seeing this tell your junior colleagues who are not on this platform to come join the discussion.
News on my 6 month battle with treatment related MDS (t-MDS) caused by my 20 year battle with high risk Multiple Myeloma. I got into a clinical trial.
myelomasurvival.com/myeloma-…
Because there is no effective treatment for t-MDS, I was on a mission to find one.
Celebrating our @NEJM paper that showed that 2 years of lenalidomide maintenance is sufficient in myeloma. A 15 year journey. The results of this trial will in my opinion save over a billion dollars a year for Medicare.
@myelomaMD as the PI worked tirelessly and I’m so fortunate to have him as a dear friend and colleague. @eaonc@theNCI
This is one of many reasons that there is slow to no progress in drug development for high risk rare diseases. In these cases a new drug trial design must be developed to expedite use for the patient to try available trials. They have little to lose and EVERYTHING to gain.